Ozempic is a once-weekly injectable prescription medication containing semaglutide, a drug that mimics a natural gut hormone to lower blood sugar, reduce cardiovascular risk, and protect kidney function in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists, which work by activating multiple systems in your body at once: prompting your pancreas to release more insulin, slowing digestion, and reducing appetite through signals in the brain.
What Ozempic Is Approved to Treat
The FDA has approved Ozempic for three specific uses in adults with type 2 diabetes. First, it’s approved alongside diet and exercise to improve blood sugar control. Second, it’s approved to reduce the risk of major cardiovascular events, specifically heart attack, stroke, and cardiovascular death, in people who also have established heart disease. Third, it’s approved to slow kidney decline and reduce the risk of end-stage kidney disease in people with type 2 diabetes and chronic kidney disease.
Ozempic is not FDA-approved for weight loss on its own. That distinction belongs to Wegovy, which contains the same active ingredient (semaglutide) but at a higher maximum dose of 2.4 mg compared to Ozempic’s 2 mg cap. Both are weekly injections, but they’re prescribed for different purposes.
How It Works in the Pancreas
Your body naturally produces a hormone called GLP-1 (glucagon-like peptide-1) in the gut after you eat. Semaglutide is a lab-made version of this hormone, engineered to last much longer in your bloodstream. When it binds to GLP-1 receptors on the insulin-producing beta cells of your pancreas, it triggers a chain reaction: levels of a signaling molecule called cyclic AMP rise inside the cell, which activates a protein that pushes insulin-containing packets to the cell’s surface and releases them into the blood. Critically, this process is glucose-dependent, meaning your pancreas ramps up insulin production only when blood sugar is elevated. That built-in safety check lowers the risk of dangerously low blood sugar compared to some older diabetes medications.
At the same time, semaglutide suppresses a second pancreatic hormone called glucagon. Glucagon normally tells your liver to release stored sugar into the bloodstream. By dialing down glucagon, the drug reduces the liver’s glucose output, which helps keep blood sugar from spiking between meals.
How It Affects Your Brain and Appetite
Blood sugar control is only part of the picture. Researchers now understand that much of semaglutide’s effect on body weight comes from its action in the central nervous system, not just the gut and pancreas. GLP-1 receptors are found throughout the brain, particularly in a brainstem region called the solitary tract nucleus, which acts as a hub for processing signals about nutrition and fullness from the digestive tract.
When semaglutide activates these brain receptors, it reduces appetite and lowers the drive to eat. Studies in animals confirmed that delivering GLP-1 directly into the brain suppresses food intake. In humans, this translates to eating smaller portions and feeling satisfied sooner. Interestingly, the gastrointestinal side effects many people experience on the drug, like nausea, also appear to be driven by the brain rather than by direct irritation of the stomach.
Slowed Digestion and Fullness
Semaglutide also slows the rate at which food leaves your stomach, a process known as gastric emptying. When your stomach empties more slowly, nutrients reach your bloodstream more gradually, which blunts the blood sugar spike that typically follows a meal. This delayed emptying also contributes to the prolonged sense of fullness many users report. However, it’s also the reason the drug can interfere with the absorption of other oral medications, something your prescriber should account for when managing multiple drugs.
Blood Sugar and Heart Benefits
In real-world use, patients taking 1 mg of Ozempic weekly saw an average blood sugar (HbA1c) reduction of 1.2 percentage points. Those who stayed on the medication consistently had an even larger drop of 1.4 percentage points. For context, a reduction of 1 point or more is considered clinically meaningful and can shift someone from poorly controlled diabetes into a much safer range.
The cardiovascular benefits are substantial. In the SELECT trial, a large randomized study of adults with overweight or obesity and established cardiovascular disease, weekly semaglutide at 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared to placebo. That composite outcome included cardiovascular death, nonfatal heart attack, and nonfatal stroke, and all three components contributed to the reduction. This is one of the reasons Ozempic has gained attention beyond blood sugar management alone.
How It’s Taken
Ozempic is injected under the skin once a week, on the same day each week, in the abdomen, thigh, or upper arm. The dose starts low and increases gradually to give your body time to adjust. You begin at 0.25 mg weekly for the first four weeks. That starting dose isn’t strong enough to meaningfully affect blood sugar; it’s purely a ramp-up phase to minimize side effects. After four weeks, the dose increases to 0.5 mg. If blood sugar control still isn’t adequate after at least another four weeks, your prescriber may raise it to 1 mg, which is the standard maximum for the diabetes indication.
Common Side Effects
Digestive symptoms are the most frequent side effects and the main reason some people stop taking the drug. Nausea, vomiting, diarrhea, abdominal pain, and constipation each occur in at least 5% of patients. In clinical trials, gastrointestinal side effects affected about 31% of patients on the 1 mg dose and 34% on the 2 mg dose. Most of these symptoms are mild to moderate and tend to improve over the first few weeks as the body adjusts, particularly during the gradual dose increases.
Severe gastrointestinal reactions were uncommon, occurring in fewer than 1% of patients. About 3% to 4% of patients on therapeutic doses discontinued the drug because of GI symptoms, compared to less than 1% on placebo.
Warnings and Who Should Not Take It
Ozempic carries the FDA’s most serious warning, a boxed warning, about the risk of thyroid tumors. In animal studies, semaglutide caused a type of thyroid cancer called medullary thyroid carcinoma. Whether this risk applies to humans is still unknown, but as a precaution, Ozempic is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a rare genetic condition called Multiple Endocrine Neoplasia syndrome type 2. It’s also contraindicated for anyone who has had a serious allergic reaction to semaglutide or any of the drug’s inactive ingredients.